RO (RO) News
Follow RO (RO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Roche launches newborn screening test for three severe genetic conditions
BERLIN, Sept. 30, 2026 // -- Roche (SIX:RO, ROP; OTCQX: RHHBY) announced today that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for ne
NEWS | Sep 30, 2026, 05:00 AM UTC
L
Genentech’s Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis
Genentech, a member of the Roche Group (SIX:RO, ROP; OTC:RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) under priority review for fenebrutin
REGULATION | Sep 30, 2026, 05:00 AM UTC
L
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
Genentech, a member of the Roche Group (SIX:RO, ROP; OTC:RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, advancing plans announced in August to increase capacity
NEWS | Sep 28, 2026, 10:00 PM UTC
L
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
EQUITY | Aug 31, 2026, 01:00 AM UTC
L
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
Qiagen owes 10x, Roche $4.8 million for infringing patents, U.S. jury says
EQUITY | Aug 28, 2026, 09:23 PM UTC
L
Roche’s Vabysmo shows sustained two-year results in difficult nAMD
Roche’s Vabysmo demonstrates sustained two-year results in difficult-to-treat neovascular age-related macular degeneration (nAMD).
EQUITY | Aug 28, 2026, 07:07 AM UTC
M
Roche gets FDA approval for ZIIHERA companion diagnostics
Roche has received FDA approval for companion diagnostic tests identifying patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA.
REGULATION | Aug 26, 2026, 06:53 PM UTC
L
Rentomojo Water Purifier Rentals See Rising Demand Across Major Indian Cities as RO, UV, and Alkaline Systems Shift to Monthly Subscriptions
Bangalore, India, July 03, 2026 (GLOBE NEWSWIRE) -- Rentomojo, a furniture and appliance rental platform
EQUITY | Jul 04, 2026, 03:30 AM UTC